

Daniela Fenoglio

Full Professor

EDUCATION AND TRAINING

1975 Scientific High School Diploma, Genoa

1980 Degree in Biological Sciences, University of Genoa

1987 Specialty School in General Pathology, University of Genoa

ACADEMIC EXPERIENCE

1982-1990 Scholarship from the National Research Council at the Chair of Immunology at the University of Genoa

1990-2000 Technical Officer VIII level at the Chair of Immunology of the University of Genoa

2000-2019 University researcher for the scientific disciplinary sector MED-09 - Department of Internal Medicine of the University of Genoa

2019 to present Associate Professor for the scientific disciplinary sector TECHNICAL SCIENCES OF LABORATORY MEDICINE MEDS/26a (formerly MEDS46)

2000-present Head of the Flow Cytometry Facility at the Center of Excellence for Biomedical Research (CEBR) of the University of Genoa

ACADEMIC POSITIONS

2024 to present Coordinator of the Master's Degree in HEALTH PROFESSIONS SCIENCES AND DIAGNOSTIC TECHNIQUES

TITLES

MAIN SEMINARS

Invited presentation at the conference organized by the European Society for Clinical Cell Analysis (ESCCA) in collaboration with the Irish Society for Cytometry in Dublin (14–16 September 2011). Title: "Th17 cells: from physiology to pathophysiology."

Invited presentation at the Symposium organized by the Society of Immunology, Clinical Immunology, and Allergology (SIICA) at the 17th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2017) in Chicago, Illinois (June 14–17, 2017). Title: "Study of T cell regulatory populations by flow cytometry."

RESULTS OBTAINED IN TECHNOLOGY TRANSFER IN TERMS OF PARTICIPATION IN THE CREATION OF NEW ENTERPRISES (SPIN OFFS), DEVELOPMENT, USE AND MARKETING OF PATENTS

Researcher in the creation of Genovax, a University of Genoa startup at the Silvano Fumero Bioindustry Park (IVREA, Turin), which operates in the field of therapeutic vaccines for chronic diseases in the field of translational medicine. Specifically: a) development of new therapeutic agents using plasmid and protein gene vaccination technology for autoimmune diseases (lupus GX 101 project); b) in the field of immunotherapies for solid tumors (prostate and kidney), evaluating the efficacy of a new therapeutic strategy for prostate cancer using telomerase peptides as immunizing agents and two adjuvants (GX 301 project covered by international patents). In December 2009, the Istituto Superiore di Sanità, the scientific arm of AIFA, authorized the Phase I clinical trial, already approved by the Ethics Committee of the San Martino Hospital in Genoa, in volunteer patients with kidney and prostate cancer. The GX 301 project passed the Phase I trial in 2011, and in September 2012 the GX301 project, with its know-how and patents, was sold to the company Mediolanum farmaceutici S.p.A. On June 30, 2014, recruitment began for the multicenter Phase II study entitled "A randomized, parallel-group, open-label Phase II trial of the immunological effects of three regimens of GX301 vaccination in castration-resistant prostate cancer patients who have achieved response to first-line chemotherapy" (EUDRACT number 2014-000095-26) with Laboratoires Leurquin Mediolanum S.A.S. as Sponsor; For this study, a panel of 3 immunological tests was used, performed at time 0, 90, and 180 on blood samples from patients recruited from the participating centers at the centralized immunological laboratory of the Center of Excellence of the University of Genoa under the responsibility of Dr. Daniela Fenoglio.

Patent application as inventor for invention No. 102015000013548 in the name of Mediolanum Farmaceutici S.p.A. for a soluble chimeric interleukin-10 receptor and its therapeutic use

Patent application as inventor for invention No. 20737281.4 (PCT/IB2020/055456) for a novel cancer vaccine, called SericumVax, developed to redirect a pre-generated immune response, induced by vaccination against a non-tumor antigen, against the tumor using antigen-loaded silk fibroin nanoparticles.

OTHER QUALIFICATIONS

Member of the Teaching Staff of the Doctorate in Clinical and Experimental Immunology at the University of Genoa from November 1, 2006 to present.

Responsible for immunological analyses performed at the CEBR as a centralized laboratory during the following clinical trials:

- Un-sponsored Phase I study "Analysis of the immunological and clinical effects induced by active immunization against immunogenic peptides derived from human telomerase in patients with stage IV renal cell carcinoma or prostate cancer" (Eudract Number 2009-011330-10).
- Multicenter Phase II study "A randomized, parallel-group, open-label Phase II trial of the immunological effects of three regimens of GX301 vaccination in castration-resistant prostate cancer patients who have achieved response to first-line chemotherapy" (EUDRACT number 2014-000095-26) with Sponsor Laboratoires Leurquin Mediolanum S.A.S. from 2009 to 2013 patients who have achieved response to first-line chemotherapy" (EUDRACT number 2014-000095-26)